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Background
The mistletoe lectin I belongs to a new class of antican-
cer drugs with type II ribosomal inhibitor activity. The
recombinant mistletoe lectin (aviscumine) has shown
immunomodulatory and cytotoxic activity in preclinical
models as well as potential antitumor effects in phase I
and I/II clinical trials. The aim of this study was to
further elucidate the immunostimulatory capacity of
aviscumine on natural killer (NK) cell function in a
human ex-vivo model.
Methods
The effect of aviscumine (0.5 and 1 ng/ml) on the cellular
cytotoxicity of NK cells isolated from peripheral blood
mononuclear cells (PBMCs) of 34 healthy volunteers was
measured via a standard Chromium51 release assay against
K562 chronic myelogenous leukemia cells. For further
validation changes in expression of the NK cell activation
marker CD107a was determined via flow cytometry
(FACS) in 13 volunteers.
Results
Aviscumine induced a significant concentration-depen-
dent increase in NK cellular cytotoxicity in about 54%
of the volunteers (p<0.001). This enhancement was also
observed with low dose IL-2 stimulation (p=0.01). FACS
analysis revealed an aviscumine triggered up-regulation
of the NK cell degranulation marker CD107a (p=0.001).
Conclusion
Functional ex-vivo analysis of NK cells from healthy
donors revealed a direct immune stimulatory mechanism
of aviscumine. These data further strengthen its potential
as immunomodulatory antitumor agent and suggest that
NK cell activity in peripherial blood may be evaluated as
predictive biomarker in clinical trials.
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